Recommendations for management of diabetes during Ramadan: update 2020, applying the principles of the ADA/EASD consensus

Mahmoud Ibrahim 1, Melanie J Davies 2, Ehtasham Ahmad 3, Firas A Annabi 4, Robert H Eckel 5, Ebtesam M Ba-Essa 6, Nuha Ali El Sayed 7, Amy Hess Fischl 8, Pamela Houeiss 9, Hinde Iraqi 10, Ines Khochtali 11, Kamlesh Khunti 2, Shabeen Naz Masood 12, Safia Mimouni-Zerguini 13, Samad Shera 14, Jaakko Tuomilehto 15 16, Guillermo E Umpierrez 17

Affiliations

01 May 2020

-

doi: 10.1136/bmjdrc-2020-001248

Abstract

Fasting the Holy month of Ramadan constitutes one of the five pillars of the Muslim faith. Although there is some evidence that intermittent fasting during Ramadan may be of benefit in losing weight and cardiometabolic risk factors, there is no strong evidence these benefits apply to people with diabetes. The American Diabetes Association/European Association for the Study of Diabetes consensus recommendations emphasize the importance of patient factors and comorbidities when choosing diabetes medications including the presence of comorbidities, atherosclerotic cardiovascular disease, heart failure, chronic kidney disease, hypoglycemia risk, weight issues and costs. Structured education and pre-Ramadan counseing are key components to successful management of patients with diabetes. These should cover important aspects like glycemic targets, self-monitoring of blood glucose, diet, physical activity including Taraweeh prayers, medication and dose adjustment, side effects and when to break the fast. The decision cycle adapted for the specific situation of Ramadan provides an aid for such an assessment. Children with type 1 diabetes should strongly be advised not to fast due to the high risk of acute complications such as hypoglycemia and probably diabetic ketoacidosis (DKA), although there is very little evidence that DKA is increased in Ramadan. Pregnant women with diabetes or gestational diabetes should be advised to avoid fasting because of possible negative maternal and fetal outcomes. Hypoglycemia is a common concern during Ramadan fasting. To prevent hypoglycemic and hyperglycemic events, we recommend the adoption of diabetes self-management education and support principles. The use of the emerging technology and continuous glucose monitoring during Ramadan could help to recognize hypoglycemic and hyperglycemic complications related to omission and/or medication adjustment during fasting; however, the cost represents a significant barrier.

Keywords: endocrinology diabetes; gestational diabetes mellitus; nutrition.


Conflict of interest statement

Competing interests: None declared.

References

  1.  
    1. Beshyah SA, Chowdhury TA, Ghouri N, et al. . Risk of diabetic ketoacidosis during Ramadan fasting: a critical reappraisal. Diabetes Res Clin Pract 2019;151:290–8. 10.1016/j.diabres.2019.02.027 - DOI - PubMed
  2.  
    1. Al-Arouj M, Bouguerra R, Buse J, et al. . Recommendations for management of diabetes during Ramadan. Diabetes Care 2005;28:2305–11. 10.2337/diacare.28.9.2305 - DOI - PubMed
  3.  
    1. Al-Arouj M, Assaad-Khalil S, Buse J, et al. . Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care 2010;33:1895–902. 10.2337/dc10-0896 - DOI - PMC - PubMed
  4.  
    1. Ibrahim M, Abu Al Magd M, Annabi FA, et al. . Recommendations for management of diabetes during Ramadan: update 2015. BMJ Open Diabetes Res Care 2015;3:e000108. 10.1136/bmjdrc-2015-000108 - DOI - PMC - PubMed
  5.  
    1. Available: https://en.wikipedia.org/wiki/Muslim_world
  6.  
    1. International Diabetes Federation IDF diabetes atlas. 9th edition Brussels, 2019. http://www.diabetesatlas.org
  7.  
    1. The Holy Qur’an Sura 2:v.183–185.
  8.  
    1. Nikfarjam M, Noormohammadi M-R, Mardanpour-Shahrekordi E. The effect of fasting on emotional intelligence. National Journal of Laboratory Medicine 2015;4:67–71.
  9.  
    1. Grajower MM, Horne BD. Clinical management of intermittent fasting in patients with diabetes mellitus. Nutrients 2019;11:E873. 10.3390/nu11040873 - DOI - PMC - PubMed
  10.  
    1. Shubrook J, Katuna J. A physician’s introduction to therapeutic fasting. When a patient asks about intermittent fasting, what information would be helpful for the physician? Intermittent fasting and type 2 diabetes | diabetes.medicinematters.com, 2019. Available: https://diabetes.medicinematters.com/diet/type-2-diabetes/intermittent-f...
  11.  
    1. Chaudhury A, Duvoor C, Reddy Dendi VS, et al. . Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol 2017;8 https://doi.org/10.3389/fendo.2017.00006 - DOI - PMC - PubMed
  12.  
    1. Davies MJ, D’Alessio DA, Fradkin J, et al. . Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 2018;41:2669–701. 10.2337/dci18-0033 - DOI - PMC - PubMed
  13.  
    1. Davies MJ, D’Alessio DA, Fradkin J, et al. . Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetologia 2018;61:2461–98. 10.1007/s00125-018-4729-5 - DOI - PubMed
  14.  
    1. Buse JB, Wexler DJ, Tsapas A, et al. . Brief update to the 2018 consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD) on the management of hyperglycaemia in type 2 diabetes. update to 2018 ADA-EASD consensus report. Diabetes Care/Diabetologia in press 2019.
  15.  
    1. Ali S, Davies MJ, Brady EM, et al. . Guidelines for managing diabetes in Ramadan. Diabet Med 2016;33:1315–29. 10.1111/dme.13080 - DOI - PubMed
  16.  
    1. Hassanein M, Al-Arouj M, Hamdy O, et al. . International diabetes Federation (IDF), in collaboration with the diabetes and Ramadan (Dar) International alliance. diabetes and Ramadan: practical guideline. review. Diabetes Res Clin Pract 2017;126:303–16. - PubMed
  17.  
    1. Available: https://www.diabetes.org.uk/about_us/news/flash-on-nhs
  18.  
    1. Steinsbekk A, Rygg Lisbeth Ø, Lisulo M, et al. . Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with meta-analysis. BMC Health Serv Res 2012;12:213. 10.1186/1472-6963-12-213 - DOI - PMC - PubMed
  19.  
    1. Powers MA, Bardsley J, Cypress M, et al. . Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American diabetes association, the American association of diabetes educators, and the Academy of nutrition and dietetics. Diabetes Care 2015;38:1372–82. 10.2337/dc15-0730 - DOI - PubMed
  20.  
    1. Chrvala CA, Sherr D, Lipman RD. Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control. Patient Educ Couns 2016;99:926–43. 10.1016/j.pec.2015.11.003 - DOI - PubMed
  21.  
    1. Zhao F-F, Suhonen R, Koskinen S, et al. . Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. J Adv Nurs 2017;73:812–33. 10.1111/jan.13163 - DOI - PubMed
  22.  
    1. Odgers-Jewell K, Ball LE, Kelly JT, et al. . Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression. Diabet Med 2017;34:1027–39. 10.1111/dme.13340 - DOI - PubMed
  23.  
    1. He X, Li J, Wang B, et al. . Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis. Endocrine 2017;55:712–31. 10.1007/s12020-016-1168-2 - DOI - PubMed
  24.  
    1. Chatterjee S, Davies MJ, Heller S, et al. . Diabetes structured self-management education programmes: a narrative review and current innovations. Lancet Diabetes Endocrinol 2018;6:130–42. 10.1016/S2213-8587(17)30239-5 - DOI - PubMed
  25.  
    1. Yorke E, Atiase Y. Impact of structured education on glucose control and hypoglycaemia in type-2 diabetes: a systematic review of randomized controlled trials. Ghana Med J 2018;52:41–60. 10.4314/gmj.v52i1.8 - DOI - PMC - PubMed
  26.  
    1. Bravis V, Hui E, Salih S, et al. . Ramadan education and awareness in diabetes (read) programme for Muslims with type 2 diabetes who fast during Ramadan. Diabet Med 2010;27:327–31. 10.1111/j.1464-5491.2010.02948.x - DOI - PubMed
  27.  
    1. Mohamed OMI, Hassanein M, Syeed A, et al. . Impact of Pre-Ramadan Intervention Program on Diabetic Patients (PRINTED 1): A Randomised Controlled Trial in a Family Medicine Clinic - Abu Dhabi. World Family Medicine 2019;17:10–22.
  28.  
    1. McEwen LN, Ibrahim M, Ali NM, et al. . Impact of an individualized type 2 diabetes education program on clinical outcomes during Ramadan. BMJ Open Diab Res Care 2015;3:e000111 10.1136/bmjdrc-2015-000111 - DOI - PMC - PubMed
  29.  
    1. Yan L, Zainudin SB, Ling C, et al. . The effect of structured education and intervention for diabetes patients during fasting in Ramadan. 18th Asean Federation of endocrine societies Congress 2015.
  30.  
    1. Almalki MH, Hussen I, Khan SA, et al. . Assessment of Ramadan education and knowledge among diabetic patients. Clin Med Insights Endocrinol Diabetes 2018;11:117955141775161. 10.1177/1179551417751611 - DOI - PMC - PubMed
  31.  
    1. Ahmedani MY, Ahsan S, Haque MSU. Role of Ramadan specific diabetes education (RSDE); a prospective study. Pak J Med Sci 2017;33:586–93. 10.12669/pjms.333.12345 - DOI - PMC - PubMed
  32.  
    1. Hossein JM, Jalali MH, Mahmoud F, et al. . Impact of structured education on diabetes management during Ramadan. International diabetes Federation 2017 Congress 2017.
  33.  
    1. Daly H, Byrne J, Martin-Stacey L, et al. . ‘A Safer Ramadan’: developing an integrated approach to support safer fasting and feasting for people with type 2 diabetes. Practical Diabetes 2014;31:292–7. 10.1002/pdi.1889 - DOI
  34.  
    1. Mnt versus nutrition education. Available: www.eatrightpro.org/payment/coding-and-billing/mnt-vs-nutrition-education [Accessed 22 Dec 2019].
  35.  
    1. Shadman Z, Akhoundan M, Poorsoltan N, et al. . Nutritional education needs in relation to Ramadan fasting and its complications in Tehran, Iran. Iran Red Crescent Med J 2016;18:e26130. 10.5812/ircmj.26130 - DOI - PMC - PubMed
  36.  
    1. Handy O, Yusof BNM, Reda WH, et al. . Chapter 7: the Ramadan nutrition plan (RNP) for patients with diabetes, 2016. Available: http://www.daralliance.org/daralliance/
  37.  
    1. Al-Mssallem MQ. Consumption of dates among Saudi adults and its association with the prevalence of type 2 diabetes. Asian J. Clin. Nutr 2018;10:58–64.
  38.  
    1. Aleid SM, Al-Khayri JM, Al-Bahrany AM. Date Palm Status and Perspective in Saudi Arabia : Al-Khayri JM, Jain SM, Johnson DV, Date palm genetic resources and utilization, volume 1. Ed Netherlands: Springer, 2015: 49–95.
  39.  
    1. Qazaq HS, Al Adeeb NZ. The consumption pattern of dates and its related food habits among UAE citizens in Al-Ain City, UAE: a pilot study. Acta Hortic 2010;882:1083–9. 10.17660/ActaHortic.2010.882.125 - DOI
  40.  
    1. Ismail B, Henry J, Haffar I, et al. . Date consumption and dietary significance in the United Arab Emirates. J Sci Food Agric 2006;86:1196–201. 10.1002/jsfa.2467 - DOI
  41.  
    1. Alkaabi JM, Al-Dabbagh B, Ahmad S, et al. . Glycemic indices of five varieties of dates in healthy and diabetic subjects. Nutr J 2011;10:59. 10.1186/1475-2891-10-59 - DOI - PMC - PubMed
  42.  
    1. Marso SP, Daniels GH, Brown-Frandsen K, et al. . Leader Steering Committee; leader trial Investigators. liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311–22. - PMC - PubMed
  43.  
    1. Marso SP, Bain SC, Consoli A, et al. . Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834–44. 10.1056/NEJMoa1607141 - DOI - PubMed
  44.  
    1. Holman RR, Bethel MA, Mentz RJ, et al. . Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:1228–39. 10.1056/NEJMoa1612917 - DOI - PubMed
  45.  
    1. Zinman B, Wanner C, Lachin JM, et al. . EMPA-REG outcome Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–28. - PubMed
  46.  
    1. Figtree GA, Rådholm K, Barrett TD, et al. . Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus. Circulation 2019;139:2591–3. 10.1161/CIRCULATIONAHA.119.040057 - DOI - PubMed
  47.  
    1. Gerstein HC, Colhoun HM, Dagenais GR, et al. . Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121–30. 10.1016/S0140-6736(19)31149-3 - DOI - PubMed
  48.  
    1. Wiviott SD, Raz I, Bonaca MP, et al. . Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–57. 10.1056/NEJMoa1812389 - DOI - PubMed
  49.  
    1. Kato ET, Silverman MG, Mosenzon O, et al. . Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 2019;139:2528–36. 10.1161/CIRCULATIONAHA.119.040130 - DOI - PubMed
  50.  
    1. Perkovic V, Jardine MJ, Neal B, et al. . CREDENCE trial Investigators. canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295–306. - PubMed

Page Navigation